

Integrating Emerging Therapies to Improve Outcomes in Renal Cell Carcinoma

Participate in the CME-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/n174

Program Faculty

Course Director

Robert J. Motzer, MD

Memorial Sloan-Kettering Cancer Center
New York, New York

CME Reviewer

Michael Heung, MD

University of Michigan Medical School
Ann Arbor, Michigan

Credit Designation

Pierre Lavalard, MBA

University of Michigan Medical School
Ann Arbor, Michigan

CME INFORMATION



This CME activity is jointly sponsored by the University of Michigan Medical School and PVI, PeerView Institute for Medical Education.



This activity is supported by an educational grant from Pfizer Inc.

PVI, PeerView Institute for Medical Education, 315 Bleecker Street, Suite 182, New York, NY 10014
Copyright © 2000-2008, PeerView Press

To complete the post-test and evaluation for CME credit
please click here: www.peerviewpress.com/pc2/n174

Integrating Emerging Therapies to Improve Outcomes in Renal Cell Carcinoma

Participate in the CME-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/n174

General Information

Requirements for Successful Completion:

In order to receive credit, participants must view all audio-visual presentations and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Certificates are awarded upon successful completion of the post-test and evaluation form.

Media: Internet

Release Date: January 21, 2008

Expiration Date: January 20, 2009

Estimated time to complete activity: 60 minutes

Sponsorship: This CME activity is jointly sponsored by the University of Michigan Medical School and PVI, PeerView Institute for Medical Education.

Support: This activity is supported by an educational grant from Pfizer Inc.

Faculty Disclosures/Conflict of Interest Policy

In accordance with ACCME requirements, the University of Michigan Medical School, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Robert J. Motzer, MD, has a financial interest/relationship or affiliation in the form of: *Grant/Research Support* from Genentech, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Wyeth Pharmaceuticals Inc.

CME Reviewer: Michael Heung, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

Credit designation: Pierre Lavalard, MBA, currently has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

To complete the post-test and evaluation for CME credit
please click here: www.peerviewpress.com/pc2/n174

Integrating Emerging Therapies to Improve Outcomes in Renal Cell Carcinoma

Participate in the CME-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/n174

Target Audience

This activity has been designed to meet the educational needs of US oncologists.

Program Description

In this case-based CME program, an expert in the treatment of renal cell carcinoma discusses advances in the use of targeted therapies and reviews how to integrate these therapies in the management of this disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Apply recent data on first-line treatment of patients with advanced renal cell carcinoma to clinical practice
- Implement appropriate strategies for use of targeted therapy for patients with advanced renal cell carcinoma, based on patient- and disease-related factors and current clinical data
- Demonstrate optimal management of advanced renal cell carcinoma in patients who have not responded to standard first-line therapy

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and PVI, PeerView Institute for Medical Education. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Michigan Medical School designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements

PeerView Press requires version 6.x browsers or higher from Microsoft or Netscape. Certain activities may require additional software to view. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Reader[®], and Adobe[®] Flash Player.

Privacy Policy

PeerView Press shares your concerns about maintaining the privacy of personal information collected on the Internet. PeerView Press ensures that confidentiality of data relating to individual visitors to a medical/health web site, including their identity, is respected by this web site. The web site owners undertake to honor or exceed the legal requirements of medical/health information privacy that apply in the country and state where the web site and mirror sites are located.

**To complete the post-test and evaluation for CME credit
please click here: www.peerviewpress.com/pc2/n174**

Integrating Emerging Therapies to Improve Outcomes in Renal Cell Carcinoma

Participate in the CME-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/n174

Privacy Policy Changes:

Minor changes to our privacy policy may occur. If privacy policies change in a way that significantly affects the way we handle personal information, we will not use the information we have previously collected without obtaining consent. We will post all privacy policy changes on our web site in a timely manner.

Collection of Personal Information from Site Users:

Visitors to PeerView Press can access and browse the site, without disclosing any personally identifiable information. PeerView Press does track some information provided by your browser, such as the time and date of access, the web site you came from, the type of browser used, and other information that does not personally identify you. Visitors registering for services such as email updates, or completing program evaluation forms are requested to provide personal information, such as name, contact information, and medical specialty. We clearly label which information is required for registration, and which information is optional, on our registration forms. PeerView Press will not collect personally identifiable information without consent and will not share this data with any external partners.

[Click here to see the full PeerView Press Privacy Policy](#)

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

To complete the post-test and evaluation for CME credit
please click here: www.peerviewpress.com/pc2/n174